M. S. Czuczman

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

M. S. Czuczman, A.J. Grillo-López, Christine A. White et al. · Journal of Clinical Oncology · 1999 · 856 citations

Medicine, Hematology, Oncology +15

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Neil L. Berinstein, A.J. Grillo-López, Christine A. White et al. · Annals of Oncology · 1998 · 523 citations · Full text

Medicine, Hematology, Oncology +15

Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma

Julie M. Vose, Brian K. Link, Michael L. Grossbard et al. · Journal of Clinical Oncology · 2001 · 416 citations

Medicine, Oncology, Pharmacotherapy +15

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Thomas E. Witzig, Julie M. Vose, Pier Luigi Zinzani et al. · Annals of Oncology · 2011 · 393 citations · Full text

Medicine, Oncology, Pharmacology +13